SCHEMBL1845748

SCHEMBL1845748

Cn1cc(NC(=O)OC(C)(C)C)cc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.39
CYP17A1 P05093 3/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
PRKDC P78527 1/20 0.37
CNR2 P34972 1/20 0.37
PTPN11 Q06124 1/20 0.36
P2RY14 Q15391 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
DRD2 P14416 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
ACHE P22303 1/20 0.36
BACE1 P56817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5001090 0.94 TOP1 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL5000911 0.94 TOP1 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL15385155 0.94 TOP1 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL14878099 0.87 CCNC (0.39) MAPK14CYP17A1CA12CA1CA9
SCHEMBL6429116 0.87 MAPK14 (0.38) MAPK14CYP17A1CA12CA1CA9
SCHEMBL2392134 0.87 HDAC3 (0.39) MAPK14CYP17A1CA12CA1CA9
SCHEMBL14099783 0.86 DAO (0.37) MAPK14PRKDCP2RY14ACHEBACE1
SCHEMBL6429813 0.85 MAPK14 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL19739304 0.85 CYP17A1 (0.44) MAPK14CYP17A1HDAC3HDAC1HDAC6
SCHEMBL13879751 0.85 P2RY12 (0.38) PRKDCP2RY14DRD2ACHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109970720-B Aurora A protein inhibitor and preparation method and pharmaceutical application thereof 深圳先进技术研究院 2020-07-03 CN claimed
CN-106674209-B Programmed death receptor 1 gene inhibitor and preparation method and application thereof 深圳先进技术研究院 2020-03-06 CN claimed
CN-122036924-A Synthetic method of bionic collagen hexapeptide 成都欣肽生物科技有限公司 2026-05-15 CN disclosed
CN-122011119-A Preparation method and application of bionic collagen cyclohexapeptide 成都欣肽生物科技有限公司 2026-05-12 CN disclosed
US-12583857-B2 Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2026-03-24 US disclosed
US-20250368628-A1 METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES DESIGN THERAPEUTICS INC (US) 2025-12-04 US disclosed
US-20250340567-A1 Next Generation Synthetic Transcription Factors WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2025-11-06 US disclosed
US-12454526-B2 Method for producing pyrrole-imidazole (poly)amide KANEKA CORPORATION (JP) 2025-10-28 US disclosed
EP-4633738-A1 CYTOTOXIC COMPOUNDS Pheon Therapeutics Ltd (GB) 2025-10-22 EP disclosed
WO-2025122764-A1 METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES Design Therapeutics, Inc. (US) 2025-06-12 WO disclosed
EP-4539839-A1 METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES Design Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2002000650-A2 NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2002-01-03 WO disclosed
US-6303312-B1 MODIFYING CELL PHENOTYPE; MEDICAL RESEARCH AND THERAPY CALIFORNIA INSTITUTE OF TECHNOLOGY 2001-10-16 US disclosed
US-6143901-A FORMINGA SPECIFIC COMPLEX BETWEEN A TARGET SEQUENCE OF DOUBLE STRANDED DNA AND AN OLIGOMER OR POLYMER OF N-METHYLPYRROLE CARBOXAMIDE AND N-METHYLIMIDAZOLE CARBOXAMID WHEREIN N-HETEROCYLCES ARE CONNCETED WITH AN AMINO ACID LINKING GROUP GENESOFT, INC. (US) 2000-11-07 US disclosed
US-6090947-A Method for the synthesis of pyrrole and imidazole carboxamides on a solid support CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2000-07-18 US disclosed
EP-0986539-A1 DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2000-03-22 EP disclosed
US-5998140-A COMPLEXES OF CELL WITH OLIGOMER THE SCRIPPS RESEARCH INSTITUTE (US) 1999-12-07 US disclosed
WO-1998049142-A1 DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1998-11-05 WO disclosed
EP-0819133-A2 COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES EPOCH PHARMACEUTICALS, INC. (US) 1998-01-21 EP disclosed
WO-1996032496-A2 COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES MICROPROBE CORPORATION (US) 1996-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583857-B2 Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines CNR1, MTNR1B, MTNR1A MAPK14 1957/4885CYP17A1 1059/4885CA12 2663/4885
US-20250368628-A1 METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES CLN6, GATAD2B, MITF MAPK14 4036/4885CYP17A1 3776/4885CA12 4783/4885
US-20250340567-A1 Next Generation Synthetic Transcription Factors ZFX, RUNX1, JUN MAPK14 3533/4885CYP17A1 2479/4885CA12 3924/4885
US-12454526-B2 Method for producing pyrrole-imidazole (poly)amide DDC, PAM, AADAC MAPK14 3034/4885CYP17A1 3552/4885CA12 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.